Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 5, 2018
Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist
CRANBURY, N.J., Feb. 5, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of ...
February 5, 2018
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
ROCKVILLE, Md., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment ...
February 5, 2018
Acer Therapeutics Expands Management Team with the Appointment of Three Executives and One New Key Hire
NEWTON, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...
February 5, 2018
Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director
WALTHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a biopharmaceutical company focused on the development of therapies to treat central nervous ...
February 5, 2018
Vermillion Announces the Grant of Two Ovarian Cancer Diagnostic Patents
AUSTIN, Texas, Feb. 5, 2018 /PRNewswire/ -- Vermillion, Inc. (VRML) announced today that it has been granted two new US patents that significantly expand coverage for ...
February 5, 2018
PolarityTE™ Provides Business Updates on Clinical Use of SkinTE™: Regeneration of Full-Thickness Skin
SALT LAKE CITY, Feb. 05, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL), today announced that initial results from the clinical applications of the commercially launched ...
February 1, 2018
Neovasc Announces Receipt of German NUB Status 1 Designation for Neovasc Reducer™ Procedure for Treatment of Refractory Angina
VANCOUVER , Feb. 1, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter ...
February 1, 2018
New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood Purification
MONMOUTH JUNCTION, N.J., Feb. 1, 2018 /PRNewswire/ -- CytoSorbents Corporation(CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation ...
January 31, 2018
Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
SAN DIEGO, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd., or Arcturus (ARCT), an RNA medicines company, today announced that it will hold an ...
January 31, 2018
Kiadis Pharma - Last Patient Dosed with ATIR101™ in the Phase II ‘008’ Clinical Trial
AMSTERDAM-DUIVENDRECHT, Netherlands--(BUSINESS WIRE)--Regulatory News: Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell therapy products ...
January 31, 2018
INNATE PHARMA : Prof. Jean-Yves Blay appointed to the Innate Pharma Supervisory Board
Marseille, France, January 31, 2018, 7:00 AM CET Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that Prof. Jean-Yves Blay has ...
January 31, 2018
Paratek Pharmaceuticals to Present at LEERINK Partners 7th Annual Global Healthcare Conference
BOSTON, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), announced today that its President, Chief Operating Officer and Chief Medical Officer, Evan Loh, ...
January 31, 2018
Intec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical Officer
JERUSALEM, Jan. 31, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (NTEC), a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion ...
January 31, 2018
Acer Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
NEWTON, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...
January 31, 2018
Catalyst Biosciences to Present Multi-Dose Subcutaneous Data for CB 2679d in Individuals with Hemophilia B in an Oral Presentation at the 11th Annual Congress of EAHAD
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
January 31, 2018
Genkyotex Reports December 31, 2017 Cash Position and Provides Business Update
ARCHAMPS, France--(BUSINESS WIRE)--Regulatory News: Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today reported cash, ...
January 31, 2018
Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)
LIVONIA, Mich., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
January 31, 2018
Zogenix Completes Enrollment in Second ZX008 Phase 3 Clinical Trial in Dravet Syndrome
EMERYVILLE, Calif., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
January 31, 2018
AIT Therapeutics Announces Completion of the Agreement to License the Revolutionary Nitric Oxide (NO) Generator and Delivery System
NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the ...
January 30, 2018
Albireo Announces Closing of $74.8 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
BOSTON, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...
Page 89 of 138